for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Deciphera Pharmaceuticals Inc

DCPH.O

Latest Trade

58.11USD

Change

0.00(0.00%)

Volume

225,295

Today's Range

58.01

 - 

60.01

52 Week Range

33.10

 - 

71.11

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
58.11
Open
59.96
Volume
225,295
3M AVG Volume
7.60
Today's High
60.01
Today's Low
58.01
52 Week High
71.11
52 Week Low
33.10
Shares Out (MIL)
56.38
Market Cap (MIL)
3,276.05
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Deciphera Pharmaceuticals Inc Earnings Release

Latest Developments

More

Deciphera Presents Data From Qinlock Program In Patients With Gastrointestinal Stromal Tumor At The European Society For Medical Oncology Virtual Congress 2020

Deciphera Says Rebastinib With Paclitaxel Showed Preliminary Clinical Benefit In Platinum-Resistant Ovarian Cancer Patients

Deciphera Announces Publication Of Qinlock Phase 1 Study Results In Patients With Gastrointestinal Stromal Tumor

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Deciphera Pharmaceuticals Inc

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.

Industry

Biotechnology & Drugs

Contact Info

200 Smith St

WALTHAM, MA

02451-0099

United States

+1.781.2096400

https://www.deciphera.com

Executive Leadership

James Arthur Bristol

Independent Chairman of the Board

Steven L. Hoerter

President, Chief Executive Officer, Director

Daniel Lee Flynn

Founder, Executive Vice President, Chief Scientific Officer

Thomas J. Kelly

Chief Financial Officer, Executive Vice President, Treasurer

Matthew L. Sherman

Executive Vice President, Chief Medical Officer

Key Stats

1.91 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-2.990

2018

-2.820

2019

-4.480

2020(E)

-5.222
Price To Earnings (TTM)
--
Price To Sales (TTM)
458.06
Price To Book (MRQ)
5.26
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-61.30
Return on Equity (TTM)
-55.68

Latest News

Latest News

BRIEF-Deciphera Announces Presentation Of Analysis Of Crossover Population From Study Of Qinlock

* DECIPHERA ANNOUNCES PRESENTATION OF ANALYSIS OF CROSSOVER POPULATION FROM THE INVICTUS PHASE 3 STUDY OF QINLOCK™ (RIPRETINIB) IN PATIENTS WITH FOURTH-LINE ADVANCED GIST Source text for Eikon: Further company coverage:

BRIEF-Deciphera Announces Health Canada's Authorization Of Qinlock

* DECIPHERA ANNOUNCES HEALTH CANADA'S AUTHORIZATION OF QINLOCK (RIPRETINIB) FOR TREATMENT OF FOURTH-LINE GASTROINTESTINAL STROMAL TUMOR Source text for Eikon: Further company coverage:

BRIEF-Deciphera Announces Publication Of Invictus Pivotal Phase 3 Study Of Qinlock In Lancet Oncology

* DECIPHERA ANNOUNCES PUBLICATION OF THE INVICTUS PIVOTAL PHASE 3 STUDY OF QINLOCK™ (RIPRETINIB) IN THE LANCET ONCOLOGY Source text for Eikon: Further company coverage:

BRIEF-Deciphera Pharmaceuticals Presents Preliminary Data From Phase 1B/2 Study Of Rebastinib In Patients With Advanced Endometrial Cancer

* DECIPHERA PHARMACEUTICALS PRESENTS PRELIMINARY DATA FROM PHASE 1B/2 STUDY OF REBASTINIB IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER AT THE ASCO 2020 VIRTUAL SCIENTIFIC PROGRAM

BRIEF-Deciphera Pharmaceuticals Announces Presentations Of Positive Patient Reported Outcomes Results From Invictus Phase 3 Study Of Qinlocktm

* DECIPHERA PHARMACEUTICALS ANNOUNCES PRESENTATIONS OF POSITIVE PATIENT REPORTED OUTCOMES RESULTS FROM INVICTUS PHASE 3 STUDY OF QINLOCKTM (RIPRETINIB) IN PATIENTS WITH FOURTH-LINE ADVANCED GIST AT THE ASCO 2020 VIRTUAL SCIENTIFIC PROGRAM

BRIEF-Amerisourcebergen Selected By Deciphera Pharmaceuticals To Support Qinlock

* AMERISOURCEBERGEN SELECTED BY DECIPHERA PHARMACEUTICALS TO SUPPORT QINLOCK™ Source text for Eikon: Further company coverage:

BRIEF-FDA Grants Full Approval Of Deciphera's Qinlock For Treatment Of Fourth-Line Gastrointestinal Stromal Tumor

* FDA GRANTS FULL APPROVAL OF DECIPHERA PHARMACEUTICALS’ QINLOCK™ (RIPRETINIB) FOR THE TREATMENT OF FOURTH-LINE GASTROINTESTINAL STROMAL TUMOR

BRIEF-Deciphera Pharmaceuticals Announces First Quarter 2020 Financial Results

* DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Deciphera Pharmaceuticals Announces Fourth Q4 Loss Per Share $1.31

* DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Deciphera Pharmaceuticals - As Of & For Quarter, Year Ended Dec 31, 2019, Expect To Have Cash, Cash Equivalents, Short-Term Investments Of About $579.0 Million

* DECIPHERA PHARMACEUTICALS - AS OF & FOR QUARTER, YEAR ENDED DEC 31, 2019, EXPECT TO HAVE CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS OF ABOUT $579.0 MILLION Source text: (http://bit.ly/38mCUvF) Further company coverage:

BRIEF-Deciphera Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* DECIPHERA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Deciphera Pharma Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing

* DECIPHERA PHARMACEUTICALS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/39s1c7q) Further company coverage:

BRIEF-Deciphera Pharmaceuticals Announces U.S. Food And Drug Administration Acceptance Of New Drug Application And Priority Review For Ripretinib

* DECIPHERA PHARMACEUTICALS ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION ACCEPTANCE OF NEW DRUG APPLICATION AND PRIORITY REVIEW FOR RIPRETINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS

Deciphera shares skyrocket as cancer drug improves progression-free survival

Deciphera Pharmaceuticals Inc's shares more than doubled on Tuesday after the drugmaker said its treatment helped stomach cancer patients live longer without their disease worsening in a late-stage study.

Deciphera Pharma's late-stage stomach cancer study meets main goal

Deciphera Pharmaceuticals Inc said on Tuesday its late-stage study met the main goal of progression-free survival in patients with a form of stomach cancer.

BRIEF-Deciphera Pharma Initiates Late Stage Study In Gastrointestinal Cancer Patients

* DECIPHERA PHARMACEUTICALS INITIATES PHASE 3 CLINICAL STUDY WITH DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (“INVICTUS” STUDY)

BRIEF-Deciphera Pharmaceuticals Announces Orphan Drug Designation From The EMA For DCC-2618 For The Treatment Of Gastrointestinal Stromal Tumors

* DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES ORPHAN DRUG DESIGNATION FROM THE EMA FOR DCC-2618 FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS Source text for Eikon: Further company coverage:

BRIEF-Deciphera Pharma reports data from ongoing phase 1 clinical study of DCC-2618 

* Deciphera Pharmaceuticals reports data from ongoing phase 1 clinical study of DCC-2618 at the 22nd annual scientific meeting and education day of the society for neuro-oncology Source text for Eikon: Further company coverage:

BRIEF-Deciphera Pharmaceuticals Q3 loss $5.85 per share​

* Deciphera Pharmaceuticals Inc announces third quarter 2017 financial results and corporate highlights

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up